Natco Pharma gets EIR from USFDA for Kothur facility

New Delhi: Drug firm Natco Pharma on Monday said it has received establishment inspection report (EIR) from the US health regulator for its Kothur facility in Telangana. The receipt of EIR from the United States Food and Drug Administration (USFDA) indicates the successful closure of inspection of the company's drug formulations facility in Kothur, Natco Pharma said in a BSE filing.

The plant was inspected from May 30 to June 5, 2019, it added.

Read Also: Natco Pharma gets zero USFDA observations for Chennai facility

Shares of Natco Pharma were trading at Rs 526.75 per scrip on the BSE, down 0.08 percent from its previous close.

Natco Pharma Limited is an Indian pharmaceutical company based in Hyderabad, Telangana, India. Established in 1981 as a private limited company, Natco Pharma develops, manufactures and markets finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The company's major product categories include Domestic Formulations, International Formulations, APIs and Blockbusters.

Read Also: Natco Pharma- Kothur facility gets 9 observations from USFDA